Business
Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
Illumina, Inc. (NASDAQ: ILMN) announced it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.
About this update from Standard Biotools Inc.
[{"type":"text","content":"Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach","length":130,"tagName":"p","attribs":{}},{"type":"text","content":"Positions Illumina to achieve growth in a large, expanding market","length":65,"tagName":"p","attribs":{}},{"type":"text","content":"Illumina and SomaLogic have partnered in proteomics co-development since late 2021","length":82,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, June 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.","length":461,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Illumina, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Illumina, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":97,"url":"https://media.zenfs.com/en/prnewswire.com/7311e89788ff020cc09ec1e2707bc7e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/H2ny3qeR8CIOnQ9TznxQLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7311e89788ff020cc09ec1e2707bc7e2","width":400,"height":97}},"href":"https://mma.prnewswire.com/media/2718501/illumina_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""The acquisition of SomaLogic will enhance Illumina's presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024. This will strengthen the value of the NovaSeq X product today and unlock greater capabilities in the future," said Jacob Thaysen, chief executive officer of Illumina. "Illumina and SomaLogic have partnered closely for more than three years, and this combination increases our ability to serve our customers and accelerate our technology roadmap towards advanced biomarker discovery and disease profiling."","length":585,"tagName":"p"},{"type":"text","content":"This transaction builds on a co-development agreement Illumina established with SomaLogic in Decemb...